PVI
BMRN icon

Pura Vida Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pura Vida Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-56,000
Closed -$5.87M – 83
2015
Q4 		$5.87M Buy
+56,000
New +$5.85M 2.48% 14

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Pura Vida Investments's BMRN Position: Q2 2022 in Review

Pura Vida Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 175,356 shares — an estimated $13.5M sold.

Pura Vida Investments first reported a position in BMRN in Q4 2017 and held it in 5 quarters. The position peaked at $15M in Q4 2021. 543 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

  • Pura Vida Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Pura Vida Investments sold 175,356 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $13.5M.
  • Pura Vida Investments first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • Pura Vida Investments's BioMarin Pharmaceuticals position peaked at $15M in Q4 2021.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.